Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bocchia

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Leukemia|August 11, 2007
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylateM Bocchia, M Ippoliti, A Gozzetti, et al.
Haematologica|October 17, 2001
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemiaF Lauria, M Lenoci, L Annino, et al.
Haematologica|December 20, 1999
Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patientsP L Zinzani, M Magagnoli, L Moretti, et al.
Blood|July 29, 1998
Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapyP L Zinzani, M Martelli, M Magagnoli, et al.
Haematologica|December 20, 1999
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?P L Zinzani, M Martelli, M Magagnoli, et al.
Blood|June 25, 1999
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patientsP L Zinzani, S Storti, A Zaccaria, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
Blood Cancer Journal|September 19, 2015
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentD Russo, M Malagola, C Skert, et al.
European Journal of Haematology|September 12, 2024
Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" StudyC Bucelli, I Capodanno, M C Miggiano, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Leukemia|August 11, 2007
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylateM Bocchia, M Ippoliti, A Gozzetti, et al.
Haematologica|October 17, 2001
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemiaF Lauria, M Lenoci, L Annino, et al.
Haematologica|December 20, 1999
Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patientsP L Zinzani, M Magagnoli, L Moretti, et al.
Blood|July 29, 1998
Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapyP L Zinzani, M Martelli, M Magagnoli, et al.
Haematologica|December 20, 1999
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?P L Zinzani, M Martelli, M Magagnoli, et al.
Blood|June 25, 1999
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patientsP L Zinzani, S Storti, A Zaccaria, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
Blood Cancer Journal|September 19, 2015
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentD Russo, M Malagola, C Skert, et al.
European Journal of Haematology|September 12, 2024
Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" StudyC Bucelli, I Capodanno, M C Miggiano, et al.
Pageof 7